EUVIMEDEUVIMED entdecken
Crossref

Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States

Michael J Dennis iD, Devin Abrahami, Maria Cecilia Vieira, Darrin Benjumea iD, Marley Boyd, Anran Shao iD, John Kelton, Sandip Pravin Patel iD

JCO Precision Oncology · 2025

DOI: 10.1200/po-24-00449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Michael J Dennis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor, Healthcare Disparities. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Guidelines recommend biomarker testing and biomarker-informed therapies in patients with metastatic non–small cell cancer (mNSCLC); however, the use remains suboptimal. METHODS To understand contemporary testing and treatment patterns, retrospective data from 42,037 patients with mNSCLC in a nationwide electronic health record–derived deidentified database from January 2011 to April 2023 were used to quantify testing rates, test positivity, and use of biomarker-informed therapies, stratified by key demographics to identify potential disparities. Multivariable logistic regression was conducted to include patient characteristics associated with the receipt of biomarker testing and subsequent biomarker-informed therapies. RESULTS A total of 34,510 patients (82.1%) received ≥one biomarker test(s). Biomarker testing and use of biomarker-informed therapies increased for all studied biomarkers ( EGFR , ALK , ROS1 , PD-L1, BRAF , RET , MET ) over time, with highest rates observed in 2023: EGFR (88.7% and 79.5%, respectively) and ALK (87.7% and 84.3%, respectively). In multivariate logistic regression, patient sex, race, Eastern Cooperative Oncology Group at baseline, insurance type, smoking status at baseline, and histology were all significantly associated with odds of receiving biomarker testing. Covariates statistically associated with receipt of biomarker-informed therapy varied by biomarker without a clear pattern of association. Although the use of biomarker testing and biomarker-informed therapies has increased in recent years, gaps and potential disparities remain. CONCLUSION Analysis of contemporary trends in biomarker testing and use of targeted therapies in mNSCLC in the United States highlight improvements in recent years. However, these rates remain suboptimal in specific strata of the patient population, including differences in racial groups and insurance groups, indicating further work is needed to bridge remaining gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHealthcare DisparitiesMolecular Targeted TherapyHumansMaleFemaleMiddle AgedUnited StatesRetrospective StudiesAgedNeoplasm MetastasisAdult

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA.
  • Pfizer Inc, New York, NY.
  • Genesis Research, LLC, Hoboken, NJ.
  • UC San Diego, La Jolla, CA.

ORCID-Profile: Michael J Dennis, Darrin Benjumea, Anran Shao, Sandip Pravin Patel

Zitieren

APA

Dennis, M. J., Abrahami, D., Vieira, M. C., Benjumea, D., Boyd, M., Shao, A., Kelton, J., & Patel, S. P. (2025). Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States. JCO Precision Oncology. https://doi.org/10.1200/po-24-00449

Vancouver

Dennis MJ, Abrahami D, Vieira MC, Benjumea D, Boyd M, Shao A, et al. Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States. JCO Precision Oncology. 2025. doi:10.1200/po-24-00449

BibTeX
@article{Dennis2025,
  author = {Dennis, Michael J and Abrahami, Devin and Vieira, Maria Cecilia and Benjumea, Darrin and Boyd, Marley and Shao, Anran and Kelton, John and Patel, Sandip Pravin},
  title = {Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-24-00449}
}
Kostenlos starten →